News

The first ankylosing spondylitis (AS) patient has been dosed in a Phase 3 trial testing SCB-808, a potential biosimilar of Enbrel (etanercept) being developed for the treatment of rheumatic diseases in China. Biosimilars are biological medical products highly similar to a reference product. They are manufactured by…

The efficacy of TNF inhibitors in slowing disease progression in people with ankylosing spondylitis (AS) may be underestimated due to inflammation when treatment is started, new research suggests. The findings were presented in a session, titled “Tumor Necrosis Factor Inhibitors Slow Radiologic Progression in Patients…

Treatment with Taltz (ixekizumab) reduces fatigue and pain in people with ankylosing spondylitis (AS) for up to one year, results from two Phase 3 trials show. The data were discussed at the 2019 American College of Rheumatology/Association for Rheumatology Professionals Annual Meeting in a presentation, titled…

Treatment with Simponi Aria (golimumab) led to clinically meaningful improvements in health-related quality of life in adults with ankylosing spondylitis after four months — benefits that were maintained over one year, a Phase 3 trial shows. The findings were presented in a poster, titled “Effects of…

The U.S. Food and Drug Administration (FDA) has approved Avsola (infliximab-axxq), a biosimilar to Remicade (infliximab), to treat active ankylosing spondylitis, its maker, Amgen, announced. The new therapy has been approved across all diseases that Remicade can treat, which in addition to active ankylosing spondylitis are moderate-to-severe rheumatoid arthritis,…

Despite skyrocketing healthcare costs, President Trump is committed to protecting the 30 million or so Americans with rare diseases and ensuring timely, affordable access to lifesaving treatments, the nation’s highest-ranking health official said. “We have to think about how our financing system can protect those with serious and rare illnesses.

Treatment with the anti-rheumatic drug Taltz (ixekizumab) leads to early and sustained reductions in pain, fatigue, and inflammation in people with non-radiographic axial spondyloarthritis (nr-axSpA), a Phase 3 trial shows. It also significantly improves quality of life for these patients, data show. The…

Rinvoq (upadacitinib), an oral therapy recently approved for rheumatoid arthritis, was effective in treating adults with active ankylosing spondylitis (AS) who failed to respond to or are not eligible for non-steroidal anti-inflammatory drugs (NSAIDs), a Phase 2/3 trial shows. After 14 weeks of treatment, taking daily…

Treatment with Cosentyx (secukinumab) provided stable reduction in disease activity, as well as less pain and better mobility in people with non-radiographic axial spondyloarthritis (nr-axSpA), a Phase 3 trial shows. Atul Deodhar, MD, the study’s lead investigator, presented the research in a session, “Secukinumab 150 mg Significantly…

Abrilada (adalimumab-afzb), a biosimilar to Humira (adalimumab), has been approved by the U.S. Food and Drug Administration (FDA) to treat people with seven inflammatory diseases, including adults with ankylosing spondylitis. Pfizer, the company that developed Abrilada, expects the therapy to be available in the U.S. starting in 2023.